Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

2026-02-22 13:13:12 ET

Redmile Group disclosed a significant reduction in its Zymeworks (NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing.

According to a February 17, 2026, SEC filing , Redmile Group reduced its stake in Zymeworks by 3,214,096 shares, with the estimated transaction value totaling $70.10 million based on the average closing price during the fourth quarter of 2025. The quarter-end value of the position decreased by $50.35 million, a result of both share sales and stock price movements.

Zymeworks is a clinical-stage biotechnology company specializing in the discovery and development of innovative cancer therapies, leveraging a robust pipeline and strategic partnerships with major pharmaceutical firms. The company’s focus on bispecific antibodies and antibody-drug conjugates positions it at the forefront of targeted oncology therapeutics. Zymeworks’ collaborative business model and proprietary technology platforms provide a competitive edge in advancing next-generation cancer treatments.

Continue reading